For the quarter ending 2025-09-30, ONCO made $710,998 in revenue. -$8,783,702 in net income. Net profit margin of -1235.40%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-06-30 |
|---|---|---|---|---|
| Cost of revenue | 34,757 | 35,991 | 55,798 | 604,132 |
| Impairment of intangible assets, indefinite-lived (excluding goodwill) | - | - | - | 1,237,140 |
| Revenue | 303,651 | 106,494 | 101,630 | 704,848 |
| Research and development | - | -111,670 | - | -3,680 |
| Gross profit | 268,894 | 70,503 | 45,832 | 100,716 |
| Selling, general and administrative | 2,341,347 | 1,523,591 | 1,674,206 | 2,221,275 |
| Research and development | -3,211 | - | 24,455 | - |
| Impairment of entadfi assets | 0 | 0 | - | - |
| Impairment of goodwill | 0 | 594,000 | 10,918,000 | 10,261,000 |
| Total operating expenses | 2,338,136 | 2,005,921 | 12,616,661 | 13,715,735 |
| Loss from operations | -2,069,242 | -1,935,418 | -12,570,829 | -13,615,019 |
| Loss on extinguishment of note payable | -5,384,719 | - | - | - |
| Loss on issuance of preferred stock and warrants | 2,543,329 | - | - | - |
| Loss on extinguishment of preferred stock | 196,244 | - | - | - |
| Interest expense | 300,069 | 223,097 | 223,592 | - |
| Change in fair value of contingent warrant liabilities | 36 | - | - | - |
| Change in fair value of warrant liabilities | -1,934,000 | 229 | 9,795 | - |
| Change in fair value of derivative liabilities | 216,000 | - | - | - |
| Fair value of subscription agreement liability | - | - | - | 248,000 |
| Other income (loss) | -8,063 | -22,660 | -5,363 | - |
| Investment income, investment expense | - | - | - | 205,146 |
| Interest expense - related party | 0 | 0 | - | - |
| Interest expense, debt | - | - | - | 156,169 |
| Change in fair value of subscription agreement liability | 0 | -191,038 | 3,319,000 | - |
| Other income | - | - | - | -31,602 |
| Gain on forgiveness of accounts payable | 0 | 0 | 944,694 | - |
| Total other expense | -6,714,460 | -437,024 | 4,024,944 | -640,917 |
| Loss before income taxes | -8,783,702 | -2,372,442 | -8,545,885 | -14,255,936 |
| Income tax benefit | 0 | 0 | - | 50,768 |
| Net loss | -8,783,702 | -2,372,442 | -8,545,885 | -14,306,704 |
| Other comprehensive income (loss), foreign currency translation adjustment, tax | - | - | - | -110,000 |
| Change in pension benefit obligation | - | - | - | -33,406 |
| Deemed dividend series c preferred stock | 0 | 328,504 | 1,170,091 | - |
| Comprehensive income (loss), net of tax, attributable to parent | - | - | - | -14,230,110 |
| Net loss applicable to common stockholders | -8,783,702 | -2,700,946 | -9,715,976 | - |
| Net loss per share, basic (in dollars per share) | -6.25 | -4.76 | -0.53 | -0.64 |
| Net loss per share, diluted (in dollars per share) | -6.25 | -4.76 | -0.53 | -0.64 |
| Weighted average number of common shares outstanding, basic (in shares) | 1,405,469 | 567,648 | 18,176,261 | 22,196,265 |
| Weighted average number of common shares outstanding, diluted (in shares) | 1,405,469 | 567,648 | 18,176,261 | 22,196,265 |
Onconetix, Inc. (ONCO)
Onconetix, Inc. (ONCO)